ESR1 and cancer: The presence of ESR1 mutations acquired during prior endocrine therapies was correlated with improved efficacy for elacestrant (12 month PFS: 26.8% vs 8.2%) [25], consistent with ESR1 mutations being a surrogate marker for cancers with preserved dependence on ER signaling.